Structural Elucidation of $β_1$ - and $β_2$ -Transferrin Using Microprobe-Capture In-Emitter Elution and High-Resolution Mass Spectrometry

Ruben Yiqi Luo^{1,2}, Christopher Pfaffroth², Samuel Yang¹, Kevin Hoang², Priscilla S.-W.

Yeung^{1,2}, James L. Zehnder^{1,2}, Run-Zhang Shi^{1,2}

¹Department of Pathology, Stanford University, Stanford, CA, USA

²Clinical Laboratories, Stanford Health Care, Palo Alto, CA, USA

Running Title: Structural Elucidation of $β_1$ - and $β_2$ -Tf Using MPIE and HR-MS

Corresponding Author: Ruben Yiqi Luo

Address: 3375 Hillview Ave, Palo Alto, CA 94304

Tel: 650-724-1318

Email: rubenluo@stanford.edu

Key Words: β₁-Transferrin, β₂-Transferrin, MPIE-ESI-MS, N-Glycan

Abstract

 $\overline{2}$

Introduction

47 electrophoresis, liquid chromatography, and enzymatic digestion-based mass spectrometry (MS) 48 by neurobiologists $(13,16–19)$. It was reported that a group of Tf glycoforms were present in ⁴⁹serum, namely serum-type Tf or sTf, among which a specific Tf glycoform (major serum-type ⁵⁰Tf) predominated (12,13); the serum-type Tf also existed in CSF, and the major serum-type Tf 51 used to be named Tf-2 in CSF (18); an additional group of Tf glycoforms were present in CSF, 52 namely brain-type Tf or Tf-1 in CSF, among which a specific Tf glycoform (major brain-type 53 Tf) was more abundant than the rest (15,20). The brain-type Tf was at least partly synthesized in 54 the CSF-producing tissue choroid plexus rather than being produced by glycosidase digestion of 55 serum-type Tf (16,20). It was found that the N-glycans on the major serum-type Tf consisted of ⁵⁶bi-antennary oligosaccharide chains with sialylated terminals, and those on the brain-type Tf are 57 desialylated, or more specifically, unsialylated (asialotransferrin) (15,16,18,20). It was 58 hypothesized that the major brain-type Tf was $β_2$ -Tf (21), but this hypothesis has not been 59 proved.

60

⁶¹In clinical cases where CSF leak is suspected, secretion samples can be collected from patients 62 and sent to clinical laboratories to test for the presence of β_2 -Tf. The conventional method to test 63 β₂-Tf as well as $β_1$ -Tf is agarose gel immunofixation electrophoresis (IFE) (2–4). Although it is 64 widely used in clinical laboratories, it does not provide structural information of the analytes. 65 Thus, the structures of $β_1$ -Tf and $β_2$ -Tf, particularly the N-glycan structures on these Tf 66 glycoforms, remained an unanswered question with this method.

68 As an emerging technology in clinical diagnostics, high-resolution mass spectrometry (HR-MS),

69 particularly top-down HR-MS, can be used to analyze a protein target in its intact state and

70 elucidate the post-translational modifications and amino acid variations in its proteoforms (22– ⁷¹24). While HR-MS is an ideal tool to analyze the Tf glycoforms, the quality of data acquired 72 during HR-MS analysis depends on sample preparation (25,26). In this article, a novel affinity 73 capture technique for sample preparation, called microprobe-capture in-emitter elution (MPIE), 74 was incorporated with HR-MS to study the Tf glycoforms (27). MPIE can directly couple a 75 label-free optical sensing technology with MS. The label-free optical sensing technology is next-76 generation biolayer interferometry (BLI, also named as thin-layer interferometry, TFI), which ⁷⁷senses optical thickness changes on the sensing surface of a microprobe caused by biomolecular ⁷⁸interactions, achieving real-time measurement without employing a reporter molecule (enzyme, 79 fluorophore, etc.) (28,29). To implement MPIE, an analyte is first captured on the surface of a 80 microprobe, and subsequently eluted from the microprobe inside an electrospray emitter. The 81 capture process is monitored in real-time via BLI. When electrospray is established from the 82 emitter to a mass spectrometer, the analyte is immediately ionized via electrospray ionization ⁸³(ESI) for HR-MS analysis. By this means, BLI and HR-MS are directly coupled in the form of ⁸⁴MPIE-ESI-MS, which is readily deployed to analyze the Tf glycoforms and elucidate the 85 structures of β₁-Tf and β₂-Tf. The study can pave a way for the development of novel clinical 86 assays for β_2 -Tf.

87

⁸⁸**Materials and Methods**

89

⁹⁰Materials and Specimens

137 rinsed in the sheath liquid for 10 s, inserted into the emitter through the regular open end, and

136 sheath liquid (10 mM ammonium formate in water); after affinity capture, the microprobe was

157 peaks of analytes were displayed in deconvoluted mass spectra at uncharged state showing

158 average molecular masses.

159

¹⁶⁰**Results**

161

162 The performance of MPIE-ESI-MS for Tf analysis was demonstrated and reported elsewhere ¹⁶³(27). MPIE-ESI-MS had a limit of detection for the Tf standard at 0.063 μg/ml, which was 164 translated to no more than 7 fmol Tf molecules captured on a microprobe (27). The high 165 analytical sensitivity and specificity provided by affinity capture made MPIE-ESI-MS an ideal 166 method to study the Tf molecules in serum, CSF, and secretion samples. The results of a set of 167 samples are shown in Figure 1. The deconvoluted mass spectrum of the serum sample showed a 168 group of MS peaks around 79554 Da; they are mainly serum-type Tf glycoforms and the 169 predominant MS peak at 79554 Da should be the major serum-type Tf (N-glycan structures 170 shown in Figure 1, see details in Discussion). The deconvoluted mass spectrum of the CSF 171 sample showed the major serum-type Tf and a group of MS peaks around 78008 Da; they are 172 mainly brain-type Tf glycoforms and the most abundant MS peak at 78008 Da should be the ¹⁷³major brain-type Tf (N-glycan structures shown in Figure 1, see details in Discussion). The ¹⁷⁴deconvoluted mass spectrum of the secretion sample showed both serum-type Tf and brain-type 175 Tf glycoforms, meaning that CSF was present in the sample. This finding was consistent with the 176 fact that the secretion sample was obtained from a patient diagnosed of CSF leak. In addition, the 177 BLI sensorgram (a time trace of label-free optical sensing responses) of each affinity capture 178 process (capture of Tf by anti-Tf Ab on a microprobe) is shown in Figure S1, allowing for real-179 time monitoring of the capture process.

180

181 To elucidate the structures of the Tf glycoforms β_1 -Tf and β_2 -Tf, after gel electrophoresis of CSF 182 samples, the extracts from the gel stripes of the β_1 -Tf and β_2 -Tf band regions were analyzed 183 using MPIE-ESI-MS. The results of a set of samples are shown in Figure 2. The deconvoluted

Discussion

253 states that a band of disialylated Tf glycoforms (disialotransferrin) may exist above the β_{2} -Tf 254 band (35). On the other hand, the unsialylated Tf glycoforms besides $β_2$ -Tf can migrate within 255 the β_2 -Tf band region and interfere with the β_2 -Tf detection. The product insert suggests that the 256 ratio of unsialylated to disialylated bands can be used to confirm the presence of β_2 -Tf. The 257 reason of this practice can be explained as follows: when CSF is present in a sample, the 258 abundance of the major unsialylated Tf glycoform β_2 -Tf significantly exceeds the minor 259 unsialylated and disialylated Tf glycoforms, resulting in a high ratio of the β_2 -Tf band to the 260 disialotransferrin band. This practice in IFE is derived from the lack of molecular structure 261 information in gel electrophoresis. However, when MS is employed, such as in the use of MPIE-262 ESI-MS, it is unnecessary to compare unsialylated and disialylated Tf glycoforms because $β_2$ -Tf 263 can be specifically detected by its accurate molecular mass, definitively differentiating it from 264 the other Tf glycoforms with different molecular masses.

266 The demonstration of MPIE-ESI-MS in detection of β_2 -Tf paved a way to establish a MS-based 267 clinical assay for β_2 -Tf. However, more factors need to be taken into consideration for this 268 purpose. When implementing the accurate molecular mass-based detection of β_2 -Tf, Tf variants 269 resulted from genetic polymorphism should be taken into consideration (11,36–39). In theory, 270 the amino acid mutations in Tf variants affect the molecular masses of β_1 -Tf and β_2 -Tf, but they 271 should not change the molecular mass difference between the two Tf glycoforms (1546 Da), 272 provided the two glycosylation sites are not modified. This hypothesis is supported by the MPIE-²⁷³ESI-MS results of a few Tf variant-containing CSF samples, as shown in Figure S2, but it needs 274 to be proved with a larger number of Tf variant samples. In addition, the glycoforms in serum-275 type Tf can vary under specific pathophysiological conditions and β_1 -Tf might not be found in

- 299 1. Warnecke A, Averbeck T, Wurster U, Harmening M, Lenarz T, Stöver T. Diagnostic Relevance of β 2-Transferrin for the Detection of Cerebrospinal Fluid Fistulas. Arch 300 Relevance of β2-Transferrin for the Detection of Cerebrospinal Fluid Fistulas. Arch 301 Otolaryngol Neck Surg. 2004 Oct 1;130(10):1178. ³⁰¹Otolaryngol Neck Surg. 2004 Oct 1;130(10):1178.
- 302 2. McCudden CR, Senior BA, Hainsworth S, Oliveira W, Silverman LM, Bruns DE, et al.
303 Evaluation of high resolution gel β_2 -transferrin for detection of cerebrospinal fluid leak 303 Evaluation of high resolution gel $β_2$ -transferrin for detection of cerebrospinal fluid leak.
304 Clin Chem Lab Med CCLM. 2013 Feb 1;51(2):311–5. Clin Chem Lab Med CCLM. 2013 Feb 1;51(2):311-5.
- 305 3. Papadea C, Schlosser RJ. Rapid Method for β2-Transferrin in Cerebrospinal Fluid Leakage
306 Using an Automated Immunofixation Electrophoresis System. Clin Chem. 2005 Feb 306 Using an Automated Immunofixation Electrophoresis System. Clin Chem. 2005 Feb
307 1;51(2):464–70. $1;51(2):464-70.$
- 308 4. Görögh T, Rudolph P, Meyer JE, Werner JA, Lippert BM, Maune S. Separation of β2-
309 Transferrin by Denaturing Gel Electrophoresis to Detect Cerebrospinal Fluid in Ear and 309 Transferrin by Denaturing Gel Electrophoresis to Detect Cerebrospinal Fluid in Ear and
310 Nasal Fluids. Clin Chem. 2005 Sep 1;51(9):1704–10. Nasal Fluids. Clin Chem. 2005 Sep 1;51(9):1704–10.
- 311 5. Zaret DL, Morrison N, Gulbranson R, Keren DF. Immunofixation to Quantify β2-Transferrin
312 in Cerebrospinal Fluid to Detect Leakage of Cerebrospinal Fluid from Skull Injury. Clin 312 in Cerebrospinal Fluid to Detect Leakage of Cerebrospinal Fluid from Skull Injury. Clin
313 Chem. 1992 Sep 1:38(9):1909–12. Chem. 1992 Sep 1;38(9):1909–12.
- 314 6. Nandapalan V, Watson ID, Swift AC. Beta-2-transferrin and cerebrospinal fluid rhinorrhoea.
315 Clin Otolaryngol. 1996 Jun;21(3):259–64. ³¹⁵Clin Otolaryngol. 1996 Jun;21(3):259–64.
- 316 7. Gallo P, Bracco F, Morara S, Battistin L, Tavolato B. The cerebrospinal fluid transferrin/Tau proteins. J Neurol Sci. 1985 Aug;70(1):81–92. proteins. J Neurol Sci. 1985 Aug; 70(1):81–92.
- 318 8. Yang F, Lum JB, McGill JR, Moore CM, Naylor SL, van Bragt PH, et al. Human transferrin:
319 CDNA characterization and chromosomal localization. Proc Natl Acad Sci. 1984 319 cDNA characterization and chromosomal localization. Proc Natl Acad Sci. 1984
320 May;81(9):2752–6. May;81(9):2752–6.
- 321 9. MacGillivray RT, Mendez E, Sinha SK, Sutton MR, Lineback-Zins J, Brew K. The complete amino acid sequence of human serum transferrin. Proc Natl Acad Sci. 1982 Apr;79(8):2504– amino acid sequence of human serum transferrin. Proc Natl Acad Sci. 1982 Apr;79(8):2504–8. ³²³8.
- 324 10. Wang S, Kaltashov IA. Identification of Reduction-Susceptible Disulfide Bonds in
325 Transferrin by Differential Alkylation Using O¹⁶/O¹⁸ Labeled Iodoacetic Acid. J / Transferrin by Differential Alkylation Using O^{16}/O^{18} Labeled Iodoacetic Acid. J Am Soc
326 Mass Spectrom. 2015 May 1;26(5):800–7. Mass Spectrom. 2015 May 1;26(5):800–7.
- 327 11. de Jong G, van Dijk JP, van Eijk HG. The biology of transferrin. Clin Chim Acta. 1990
328 Sep;190(1–2):1–46. Sep;190(1–2):1–46.
- 329 12. de Jong G, van Eijk HG. Microheterogeneity of human serum transferrin: A biological
330 benomenon studied by isoelectric focusing in immobilized pH gradients. Electrophore 330 phenomenon studied by isoelectric focusing in immobilized pH gradients. Electrophoresis.
331 1988;9(9):589–98. ³³¹1988;9(9):589–98.
- 332 13. de Jong G, van Noort WL, van Eijk HG. Carbohydrate analysis of transferrin subfractions
333 isolated by preparative isoelectric focusing in immobilized pH gradients. Electrophoresis. 333 isolated by preparative isoelectric focusing in immobilized pH gradients. Electrophoresis.
334 1992;13(1):225–8. ³³⁴1992;13(1):225–8.

335 14. Delaroche O, Bordureb P, Lippert E, Sagnieza M. Perilymph detection by β2-transferrin
336 immunoblotting assay. Application to the diagnosis of perilymphatic fistulae. Clin Chim 336 immunoblotting assay. Application to the diagnosis of perilymphatic fistulae. Clin Chim
337 Acta. 1996 Feb; 245(1): 93–104. Acta. 1996 Feb; 245(1): 93-104.

- 338 15. Hoffmann A, Nimtz M, Getzlaff R, Conradt HS. 'Brain-type' *N* -glycosylation of asialotransferrin from human cerebrospinal fluid. FEBS Lett. 1995 Feb 13;359(2-3):164-8.
- 340 16. Futakawa S, Nara K, Miyajima M, Kuno A, Ito H, Kaji H, et al. A unique N-glycan on human transferrin in CSF: a possible biomarker for iNPH. Neurobiol Aging. 2012 341 human transferrin in CSF: a possible biomarker for iNPH. Neurobiol Aging. 2012
342 Aug: 33(8): 1807–15. Aug; 33(8): 1807–15.
- 343 17. Brown KJ, Vanderver A, Hoffman EP, Schiffmann R, Hathout Y. Characterization of transferrin glycopeptide structures in human cerebrospinal fluid. Int J Mass Spectrom. 344 transferrin glycopeptide structures in human cerebrospinal fluid. Int J Mass Spectrom. 2012
345 Feb:312:97–106. Feb;312:97-106.
- 346 18. Nagae M, Morita-Matsumoto K, Arai S, Wada I, Matsumoto Y, Saito K, et al. Structural
347 change of N-glycan exposes hydrophobic surface of human transferrin. Glycobiology. 20 347 change of N-glycan exposes hydrophobic surface of human transferrin. Glycobiology. 2014
348 Aug 28;24(8):693–702. Aug 28;24(8):693–702.
- 349 19. Hoshi K, Ito H, Abe E, Fuwa TJ, Kanno M, Murakami Y, et al. Transferrin Biosynthesized
350 in the Brain Is a Novel Biomarker for Alzheimer's Disease. Metabolites. 2021 Sep 350 in the Brain Is a Novel Biomarker for Alzheimer's Disease. Metabolites. 2021 Sep
351 10:11(9):616. 10;11(9):616.
- 352 20. Hoshi K, Matsumoto Y, Ito H, Saito K, Honda T, Yamaguchi Y, et al. A unique glycan-
353 isoform of transferrin in cerebrospinal fluid: A potential diagnostic marker for neurologic 353 isoform of transferrin in cerebrospinal fluid: A potential diagnostic marker for neurological
354 diseases. Biochim Biophys Acta BBA - Gen Subj. 2017 Oct;1861(10):2473–8. diseases. Biochim Biophys Acta BBA - Gen Subj. 2017 Oct;1861(10):2473–8.
- 355 21. Caslavska J, Schild C, Thormann W. High□resolution capillary zone electrophoresis and
256 mass spectrometry for distinction of undersialy lated and hypoglycosylated transferring 356 mass spectrometry for distinction of undersialylated and hypoglycosylated transferrin
357 glycoforms in body fluids. J Sep Sci. 2020 Jan;43(1):241–57. glycoforms in body fluids. J Sep Sci. 2020 Jan; $43(1):241-57$.
- 22. Siuti N, Kelleher NL. Decoding protein modifications using top-down mass spectrometry.
359 Nat Methods. 2007 Oct;4(10):817–21. Nat Methods. 2007 Oct;4(10):817–21.
- 360 23. Brown KA, Melby JA, Roberts DS, Ge Y. Top-down proteomics: challenges, innovations,
361 and applications in basic and clinical research. Expert Rev Proteomics. 2020 Oct 361 and applications in basic and clinical research. Expert Rev Proteomics. 2020 Oct 2:17(10):719–33. ³⁶²2;17(10):719–33.
- 363 24. Luo RY, Wong C, Xia JQ, Glader BE, Shi RZ, Zehnder JL. Neutral-Coating Capillary
364 Electrophoresis Coupled with High-Resolution Mass Spectrometry for Top-Down 364 Electrophoresis Coupled with High-Resolution Mass Spectrometry for Top-Down
365 Identification of Hemoglobin Variants. Clin Chem. 2022 Oct 29:hvac171. Identification of Hemoglobin Variants. Clin Chem. 2022 Oct 29;hvac171.
- 366 25. Donnelly DP, Rawlins CM, DeHart CJ, Fornelli L, Schachner LF, Lin Z, et al. Best practices and benchmarks for intact protein analysis for top-down mass spectrometry. Nat Methods. 367 and benchmarks for intact protein analysis for top-down mass spectrometry. Nat Methods.
368 2019 Jul:16(7):587–94. 2019 Jul;16(7):587–94.

- 369 26. Padula M, Berry I, O'Rourke M, Raymond B, Santos J, Djordjevic SP. A Comprehensive
370 Guide for Performing Sample Preparation and Top-Down Protein Analysis. Proteomes. 20 370 Guide for Performing Sample Preparation and Top-Down Protein Analysis. Proteomes. 2017
371 Apr 7:5(4):11. Apr 7;5(4):11.
- 372 27. Luo RY, Yang S. Using Microprobe-Capture In-Emitter Elution to Directly Couple Label-
373 Free Optical Sensing Technology with Mass Spectrometry for Top-Down Protein Analysis 373 Free Optical Sensing Technology with Mass Spectrometry for Top-Down Protein Analysis
374 [Internet]. Chemistry; 2022 Oct [cited 2022 Oct 25]. Available from:
- 374 [Internet]. Chemistry; 2022 Oct [cited 2022 Oct 25]. Available from:
375 https://chemrxiv.org/engage/chemrxiv/article-details/6352339055a08
- ³⁷⁵https://chemrxiv.org/engage/chemrxiv/article-details/6352339055a0816c28bee4cb
- 376 28. Luo YR, Chakraborty I, Lazar-Molnar E, Wu AHB, Lynch KL. Development of Label-Free
377 Immunoassays as Novel Solutions for the Measurement of Monoclonal Antibody Drugs and 377 Immunoassays as Novel Solutions for the Measurement of Monoclonal Antibody Drugs and
378 Antidrug Antibodies. Clin Chem. 2020 Oct 1:66(10):1319–28. ³⁷⁸Antidrug Antibodies. Clin Chem. 2020 Oct 1;66(10):1319–28.
- 379 29. Luo YR, Yun C, Chakraborty I, Wu AHB, Lynch KL. A SARS-CoV-2 Label-Free Surrogate
380 Virus Neutralization Test and a Longitudinal Study of Antibody Characteristics in COVID-380 Virus Neutralization Test and a Longitudinal Study of Antibody Characteristics in COVID-
381 19 Patients. Tang YW, editor. J Clin Microbiol [Internet]. 2021 Jun 18 [cited 2021 Nov 381 19 Patients. Tang YW, editor. J Clin Microbiol [Internet]. 2021 Jun 18 [cited 2021 Nov
382 4];59(7). Available from: https://journals.asm.org/doi/10.1128/JCM.00193-21
- ³⁸²4];59(7). Available from: https://journals.asm.org/doi/10.1128/JCM.00193-21
- 383 30. Bieberich E. Synthesis, Processing, and Function of N-glycans in N-glycoproteins. In: Yu RK, Schengrund CL, editors. Glycobiology of the Nervous System [Internet]. New York, 384 RK, Schengrund CL, editors. Glycobiology of the Nervous System [Internet]. New York,
385 NY: Springer New York; 2014 [cited 2021 Dec 6]. p. 47–70. (Advances in Neurobiology; 385 NY: Springer New York; 2014 [cited 2021 Dec 6]. p. 47–70. (Advances in Neurobiology; vol. 9). Available from: http://link.springer.com/10.1007/978-1-4939-1154-7 3 vol. 9). Available from: http://link.springer.com/10.1007/978-1-4939-1154-7_3
- 387 31. Cao L, Diedrich JK, Ma Y, Wang N, Pauthner M, Park SKR, et al. Global site-specific
388 analysis of glycoprotein N-glycan processing. Nat Protoc. 2018 Jun;13(6):1196–212. analysis of glycoprotein N-glycan processing. Nat Protoc. 2018 Jun;13(6):1196–212.
- 389 32. Maier M, Reusch D, Bruggink C, Bulau P, Wuhrer M, Mølhøj M. Applying mini-bore
390 HPAEC-MS/MS for the characterization and quantification of Fc N -glycans from 390 HPAEC-MS/MS for the characterization and quantification of Fc N -glycans from
391 heterogeneously glycosylated IgGs. J Chromatogr B. 2016 Oct:1033–1034:342–52 heterogeneously glycosylated IgGs. J Chromatogr B. 2016 Oct;1033-1034:342-52.
- 392 33. Kleinert P, Kuster T, Durka S, Ballhausen D, Bosshard NU, Steinmann B, et al. Mass
393 Spectrometric Analysis of Human Transferrin in Different Body Fluids. Clin Chem La 393 Spectrometric Analysis of Human Transferrin in Different Body Fluids. Clin Chem Lab
394 Med. 2003 Jan 4:41(12):1580–8. Med. 2003 Jan 4;41(12):1580-8.
- 395 34. Coddeville B, Carchon H, Jaeken J, Briand G, Spik G. Determination of glycan structures
396 and molecular masses of the glycovariants of serum transferrin from a patient with 396 and molecular masses of the glycovariants of serum transferrin from a patient with
397 carbohydrate deficient syndrome type II. Glycoconj J. 1998;15(3):265–73. carbohydrate deficient syndrome type II. Glycoconj J. 1998;15(3):265–73.
- 398 35. HYDRAGEL 6 ß2 TRANSFERRIN(E) Kit Instruction Manual. Sebia; 2011.
- 399 36. Caslavska J, Lanz C, Burda P, Tobler M, Thormann W. Analysis of genetic variants of transferrin in human serum after desialylation by capillary zone electrophoresis and cap 400 transferrin in human serum after desialylation by capillary zone electrophoresis and capillary
401 isoelectric focusing. J Sep Sci. 2017 Jun;40(11):2488–97. isoelectric focusing. J Sep Sci. 2017 Jun; 40(11): 2488–97.
- 402 37. Lee PL, Halloran C, Trevino R, Felitti V, Beutler E. Human transferrin G277S mutation: a
403 tisk factor for iron deficiency anaemia: Transferrin G277S Mutation and Anaemia. Br J 403 risk factor for iron deficiency anaemia: Transferrin G277S Mutation and Anaemia. Br J
404 Haematol. 2001 Nov;115(2):329–33. Haematol. 2001 Nov;115(2):329–33.

- 405 38. Pang H, Koda Y, Soejima M, Kimura H. Identification of a mutation (A1879G) of transferrin
406 from cDNA prepared from peripheral blood cells. Ann Hum Genet. 1998 May;62(3):271–4. from cDNA prepared from peripheral blood cells. Ann Hum Genet. 1998 May;62(3):271–4.
- 407 39. Evans RW, Crawley JB, Garratt RC, Grossmann JG, Neu M, Aitken A, et al.
408 Characterization and Structural Analysis of a Functional Human Serum Trans
- 408 Characterization and Structural Analysis of a Functional Human Serum Transferrin Variant
409 and Implications for Receptor Recognition. Biochemistry. 1994 Oct 18;33(41):12512–20.
- and Implications for Receptor Recognition. Biochemistry. 1994 Oct 18;33(41):12512–20.

⁴¹¹**Tables**

⁴¹⁵**Figure Captions**

- 417 Figure 1. (A) Experiment workflow of MPIE-ESI-MS for Tf analysis. The MPIE-ESI-MS results
- 418 of (B) a serum sample, (C) a CSF sample, and (D) a secretion sample from a patient diagnosed of
- ⁴¹⁹CSF leak: HR-MS raw mass spectra (left) and deconvoluted mass spectra (right) of captured Tf
- 420 molecules, showing serum-type Tf in (B), and both serum-type Tf and brain-type Tf in (C) and

 421 (D).

423 Figure 2. The MPIE-ESI-MS results of (A) the extract from the gel stripe of the β_1 -Tf band

424 region and (B) the extract from the gel stripe of the β_2 -Tf band region: HR-MS raw mass spectra

425 (left) and deconvoluted mass spectra (right) of captured Tf molecules, showing β_1 -Tf in (B) and

426 β_2 -Tf in (C).

⁴²⁸Figure 3. (A) Primary structure of human transferrin, showing the sequence of 679 amino acids, 429 19 disulfide bonds, and 2 N-glycosylation sites. (B) N-glycan structures on β_1 -Tf (major serum-430 type Tf) and β_2 -Tf (major brain-type Tf), confirmed by comparing the theoretical molecular ⁴³¹masses of the Tf glycoforms with the measured molecular masses in Figure 1, Figure 2, and

432 Table 1.

(C)

Figure 2

(A)

Figure 3

(A) VPDKTVRWOA VSEHEATKOQ SFRDHMKSVI PSDGPSVAOV KKASYLDOIR AIAANEADAV TLDAGLVYDA YLAPNNLKPV VAEFYGSKED POTFYYAVAV VKKDSGFOMN OLRGKKSCHT GLGRSAGWNI PIGLLYCDLP EPRKPLEKAV ANFFSGSCAP CADGTDFPOL COLCPGCGCS TLNQYFGYSG AFKGLKDGAG DVAFVKHSTI FENLANKADR DQYELLGLDN TRKPVDEYKD GHLAQVPSHT VVARSMGGKE DLIWELLNQA OEHFGKDKSK EFOLFSSPHG KDLLFKDSAH GFLKVPPRMD AKMYLGYEYV TAIRNLREGT OPEAPTDEOK PVKWOALSHH ERLKODEWSV NSVGKIE<mark>GVS AETTEDGIAK IMNGEADAMS LDGGFVYIAG KO</mark>GLVPVLAE NYNKSDNOED TPEAGYFAVA VVKKSASDLT WDNLKGKKSO HTAVGRTAGW NIPMGLLYNK INHORFDEFF SEGOAPGSKK DS\$LOKLOMG SGLNLOEPNN KEGYYGYTGA FROLVEKGDV AFVKHQTVPQ NTGGKNPDPW AKNLNEKDYE LLOLDGTRKP VEEYANCHLA RAPNHAVVTR KDKEACVHKI LRQQQHLFGS NVTDCSGNFC LFRSETKDLL FRDDTVCLAK LHDRNTYEKY LGEEYVKAVG NLRKCSTSSL LEACTFRRP

Primary Structure of Human Transferrin: 679 AA, 19 Disulfide Bonds (Orange Label), 2 N-Glycosylation Sites (Blue Label)

Theoretical Molecular Mass: 79554.71 Da Theoretical Molecular Mass: 78008.35 Da

Measured Molecular Mass: 79554.04 Da – 79554.81 Da Measured Molecular Mass: 78008.03 Da – 78008.83 Da